Final results from independent clinical study of ColdZyme® show duration of illness lowered by approximately 5 days.
The University of Kent has published final results for the Primary Endpoint from the now completed double-blind, placebo-controlled, randomized trial. The study now completed is an independent, investigator initiated in vivo study led by Glen Davison, professor of sports and exercise science and researcher in exercise immunology at the University of Kent, in England."The final analysis of the completed is still ongoing, but data for the primary endpoint, namely the duration of URTI infection are now final. The findings are really exciting as they show statistically significant reduction